文献综述-肝癌介入治疗的现状+课题设计ppt

摘要：肝癌是世界上第三大最常见的致死性癌症。肝癌的治疗手段需要多学科技术的参与，具体实施取决于肿瘤病程的分期、病人的身体机能和肝功能。在过去的数年内，肝癌的手术治疗和局部治疗取得重大的进展，短期存活率提高，但复发和转移依旧是治疗的难题。对于中晚期肝癌患者而言，介入治疗是近年来应用较为广泛的一种微创治疗手段，通过注射特殊的药剂进入肿瘤的血管，直接干预肿瘤的生长，破坏组织，促进肿瘤细胞的凋亡，具有良好的治愈效果。本文对介入治疗进行深入分析，收集其参与体内免疫系统的调节，促进或抑制癌症相关的信号通路的作用，进一步阐述治疗手段的作用机制，并为治疗手段的发展和靶向提供新的启发和理论支持。
关键词：肝癌、介入治疗、信号通路、免疫系统

Abstract: 

Hepatocellular carcinoma is the third most common death-related type of cancer. The treatments for hepatocellular carcinoma patients require multidisciplinary technical participation with the specific implemention depending on the cancer staging, physical status of patients and liver function.In the past few years, a great progression has been made in operation therapy and local treatment of Hepatocellular carcinoma by increasing the short-term survival rate. But it’s still a huge problem the recurrence and metastasisi of tumor issues. For patients with adcanced cancer, Interventional therapy is a widely used minimally invasive treatment in recent years. By injecting some special agent into the tumor vessels or other non-cascular cavities, the tumor issue would obtain an inhibition of the growth and induction of the apoptosis of cancer cells. This article has taken a depth analysis on interventional therapy mechanism, including the regulation of the immune system and cancer-related signal pathway, and provide new inspiration and theoretical supporting for therapy of hepatocellular carcinoma.
Key words: Hepatocellular carcinoma (HCC), interventional therapy, treatment mechanism 

（一） 肝癌的分期
表1. BCLC肝癌分期参照表
图1. 肝癌分期和治疗方案对照图
 
（二） 肝癌的非血管性介入治疗
（1）射频消融治疗
（2）化学消融治疗
（三） 血管性介入治疗
（1） 肝动脉化疗栓塞
（2） 药物洗脱珠化疗栓塞
（四） 联合介入治疗
（1） TACE+射频消融
（2） TACE+化学消融
（3） TACE+基因治疗

文献

1. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760-9.
2. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Seminars in cancer biology. 2014;26:78-88.
3. Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Annals of surgical oncology. 2008;15(4):972-8.
4. Karaman B, Battal B, Sari S, Verim S. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World journal of gastroenterology : WJG. 2014;20(47):18059-60.
5. Duseja A. Staging of hepatocellular carcinoma. Journal of clinical and experimental hepatology. 2014;4(Suppl 3):S74-9.
6. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004;10(2 Suppl 1):S115-20.
7. Yang T, Lin C, Zhai J, Shi S, Zhu M, Zhu N, et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. Journal of cancer research and clinical oncology. 2012;138(7):1121-9.
8. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of hepatology. 2006;44(4):723-31.
9. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54(3):411-8.
10. Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer imaging : the official publication of the International Cancer Imaging Society. 2012;12:79-88.
11. Dupuy DE, Goldberg SN. Image-guided rad